GSK3179106
Sponsors
GlaxoSmithKline
Conditions
Irritable Bowel Syndrome
Phase 1
A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers
CompletedNCT02727283
Start: 2015-11-26End: 2016-03-18Updated: 2017-05-08
A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects
CompletedNCT02798991
Start: 2016-06-30End: 2016-11-30Updated: 2017-01-18